The Latest Cardiac and Vascular News
New clinical data shows Cardiologs’ deep learning model can predict the short-term risk of atrial fibrillation (AFib) based on 24-hour Holter recordings that show normal sinus rhythm PARIS and BOSTON, March 31, 2022 /PRNewswire/ — Cardiologs today announced a poster presentation at the 2022 American College of Cardiology (ACC) meeting in Washington, DC, from April 2-4, 2022. The […]
Transparent 3D models allow MedTech companies to train physicians on new devices outside the cath lab BOSTON, March 31, 2022 /PRNewswire/ — Biomodex®, the leader in biorealistic haptic simulators for physician training and rehearsals, today announced the launch of Clear Cartridges for use with all Biomodex EVIAS™ and EVIAS Plus™ stations. The anatomically accurate clear cartridges […]
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. REGULATED INFORMATION – INSIDE INFORMATION LIÈGE, Belgium, March 31, 2022 (GLOBE NEWSWIRE) — Hyloris Pharmaceuticals SA (Euronext Brussels: […]
Shockwave M5+ IVL Catheter Broadens Options for Treatment of Peripheral Arteries SANTA CLARA, Calif., March 31, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the global commercial availability of the Shockwave M5+ peripheral […]
Innovations designed to seamlessly work together, strengthen clinical confidence, build efficiency throughout the care pathway, and improve cardiac care experiences Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new additions to its innovative integrated portfolio of cardiology solutions at the American College […]
PARIS, March 31, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat resistant/hard-to-treat hypertension and heart failure, announced the publication of a new scientific article reporting the efficacy of its second drug-candidate, […]
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided key business updates. “This past quarter […]
Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing Mavacamten granted breakthrough therapy designation in China for the treatment of patients with oHCM Infigratinib approved under special named patient program for the treatment of cholangiocarcinoma (CCA) in the Bo’Ao pilot zone of Hainan […]
Initiated IMPAHCT, a global Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH) in December 2021 Received FDA guidance in April 2021 that our Phase 2b/Phase 3 trial could support an NDA submission based on change in six minute walk distance as the primary endpoint for the Phase […]
CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended December 31, 2021. Recent Highlights: Reported revenue […]
